Abstract
The incorporation of tyrosine kinase inhibitors (TKIs) into chemotherapy regimens has significantly improved the long-term survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Successive generations of TKIs with increased potency against BCR-ABL and broader spectrum of activity against ABL kinase domain mutations have led to incremental improvements in the outcomes of patients with this disease. In particular, ponatinib, a potent pan-BCR-ABL TKI capable of overcoming the T315I mutation, holds significant promise in the treatment of Ph+ ALL, although the potential cardiovascular toxicity of this agent remains a concern. With the development of more potent TKIs that are capable of inducing deep and sustained remissions, future studies re-evaluating the need for intensive chemotherapy as well as the role for stem cell transplantation in first remission for patients with Ph+ ALL are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 193-200 |
Number of pages | 8 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 30 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2017 |
Keywords
- Acute lymphoblastic leukemia
- Dasatinib
- Imatinib
- Philadelphia chromosome
- Ponatinib
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry